Costs and Expenses in USD of Inhibikase Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Costs and Expenses history and change rate from Q1 2020 to Q3 2025.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2025 was $12.8M, a 119% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2025 was $51.1M, a 155% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2024 was $28.6M, a 40.5% increase from 2023.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2023 was $20.4M, a 11.5% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2022 was $18.3M, a 2.16% increase from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Change (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Change (%)

Inhibikase Therapeutics, Inc. Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $51.1M $12.8M +$6.94M +119% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 $44.2M $10.8M +$5.78M +114% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $38.4M $14.6M +$9.82M +205% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $28.6M $12.9M +$8.53M +194% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 $20.1M $5.83M +$979K +20.2% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-14
Q2 2024 $19.1M $5.05M -$1.27M -20.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $20.4M $4.78M +$2.89K +0.06% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $20.4M $4.4M +$5.03K +0.11% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 $20.3M $4.85M +$328K +7.26% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $20M $6.32M +$1.67M +36% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $18.3M $4.78M +$92.8K +1.98% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $18.3M $4.4M -$645K -12.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $18.9M $4.52M -$279K -5.82% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $19.2M $4.65M +$655K +16.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $18.5M $4.69M +$654K +16.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $17.9M $5.04M +$3.67M +268% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $14.2M $4.8M +$4.1M +584% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.1M $3.99M +$3.36M +530% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $6.74M $4.03M +$3.22M +397% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $3.52M $1.37M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $701K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $634K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $811K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17

Inhibikase Therapeutics, Inc. Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $28.6M +$8.24M +40.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 $20.4M +$2.1M +11.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 $18.3M +$385K +2.16% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-27
2021 $17.9M +$14.3M +408% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $3.52M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.